to boost late-stage development of novel therapy to treat life-threatening, virus-induced
by the “InnovFin
EU-finance for innovators”
The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening keynote and award lecture of this year’s ESMO Immuno-Oncology Congress in Geneva, Switzerland, on December 13, 2018 (01:30-01:45 pm CET, Hall A2 – Room A). The title of his lecture
Leiden, The Netherlands, September 27, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2 combination trial with ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody and PD-1 checkpoint inhibitor (NCT02426892). The open-label trial in patients with HPV-16 associated cancers demonstrated safety and efficacy, resulting in an improved survival as compared to historical nivolumab monotherapy results. It was conducted by MD Anderson Cancer Center in collaboration with ISA Pharmaceuticals and Bristol-Myers Squibb. The results are published in JAMA Oncology today (doi:10.1001/jamaoncol.2018.4051; https://jamanetwork.com/journals/jamaoncology/article-abstract/2703886)
Leiden, The Netherlands, May 23, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018. He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013.
“We would like to thank Ronald Loggers for his leadership during the past five years and his contribution in developing ISA Pharmaceuticals into a leading European immuno-oncology player,” said Bart Bergstein, Chairman of ISA´s Board of Directors. “We look forward to further advancing ISA´s pipeline and commercial reach and are
-Experienced Chief Medical Officer to advance ISA´s clinical pipeline
Leiden, The Netherlands, April 30, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Leon Hooftman, MD, to the position of Chief Medical Officer (CMO), effective May 1, 2018. He brings many years of experience in drug development and academic research and has a strong track record in early- and late-stage clinical development with specific expertise in immuno-oncology.
“As we are planning to start two new clinical programs with ISA101b together with Regeneron as well as other clinical
Leiden, The Netherlands, April 26, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX).
The goal of the open-label Phase II study in patients with HPV16-positive, incurable oropharyngeal cancer is to investigate whether a combination of ISA101b with Utomilumab is able to shrink or slow the growth of tumors. The safety of the
– AMPLIVANT-Modi-1 conjugate expected to enter clinic in H1 2019
– Collaboration seeks to further leverage Moditope® platform
Leiden, The Netherlands, and Oxford, UK, 15 February, 2018 — ISA Pharmaceuticals B.V. (‘ISA’), a clinical-stage immunotherapy company, and Scancell Holdings plc, (‘Scancell’ or the ‘Company’), the developer of novel immunotherapies for the treatment of cancer, are pleased to announce that they have entered into a worldwide licensing and collaboration agreement to use ISA’s AMPLIVANT® adjuvant technology for the manufacturing, development and commercialisation of Scancell’s first Moditope® development candidate, Modi-1. This partnership has the potential to provide a new treatment option for patients with
Leiden, The Netherlands, January 3, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square.
Ronald Loggers, CEO of ISA Pharmaceuticals, will present at Biotech Showcase™ as follows:
Date: Tuesday, January 9, 2018
Time: 9:45am (PST)
Room: Hilton / Franciscan C, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary
Leiden, The Netherlands, December 18, 2017, – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. Regeneron and ISA will jointly fund and conduct clinical trials of the combination treatment in cervical cancer and head-and-neck cancer.
Expression of HPV oncoproteins contributes to the development of cervical and head-and-neck cancers, and approximately 55 percent of cervical cancers and over 60 percent of head-and-neck cancers are HPV16 positive.